

**In case of emergency, or if you find this card,
please contact the doctor listed below:**

Doctor's Name/Clinic, Centre or Hospital Name:

Telephone contact:

DARZALEX®
daratumumab

Johnson & Johnson

CP-499232 January 2025

IMPORTANT INFORMATION ABOUT BLOOD TRANSFUSIONS

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed in the package leaflet.
All side effects should be reported.

Reporting forms and information can be found at
<https://yellowcard.mhra.gov.uk/> or search for **MHRA Yellow Card**
in the Google Play or Apple App Store.

Side effects should also be reported to Janssen-Cilag Limited
on **01494 567447** or at **dsafety@its.jnj.com**. By reporting side effects
you can help provide information on the safety of this medicine.

Daratumumab patients: Provide this card to healthcare providers BEFORE blood transfusion and carry it for 6 months after treatment has ended. For further information, please refer to the Patient Information Leaflet

Patient ID Card for DARATUMUMAB

Name: _____

Date of Birth: _____ NHS Number: _____

I am taking the following medication:

Daratumumab antibody product for the treatment of multiple myeloma or AL Amyloidosis

I stopped taking this medication on ____ / ____ / ____
DD MM YYYY

Dear Healthcare Provider,

Daratumumab is associated with the risk of interference with blood typing. The indirect Coombs test (indirect antiglobulin test [IAT]) may show positive results in patients taking daratumumab, even in the absence of antibodies to minor blood antigens in the patient's serum, which may persist for up to 6 months after the last dose. The determination of a patient's ABO and Rh blood type are not impacted.

If an emergency transfusion is required, non-cross-matched, ABO/RhD-compatible RBCs can be given per local blood bank practices.

For further information, please contact Johnson & Johnson Medical Information on 01494 567 444 or email at: medinfo@its.jnj.com

Additional information on interference with blood compatibility testing can be found on the emc website: <http://www.medicines.org.uk/emc/> and searching for the Darzalex Summary of Product Characteristics.

Before starting daratumumab my blood test results collected on

____ / ____ / ____ **were:**
DD MM YYYY

Blood type: A B AB O RhD+ RhD-
☐ ☐ ☐ ☐ ☐ ☐

Indirect Coombs test (antibody screen) was:

Negative

☐

Positive for the following antibodies:

☐

Other: _____

Contact details of institution where the blood tests were performed:
